[October 20, 2016] |
|
NeuroMetrix Reports Q3 2016 Financial Results
NeuroMetrix, Inc. (Nasdaq: NURO, NUROW), today reported financial and
business highlights for the quarter and nine month periods ended
September 30, 2016.
The Company operates in two markets - wearable therapeutic technology
and point-of-care diagnostic tests. The Company's two primary products
are Quell® and DPNCheck®. Quell is an
over-the-counter wearable neurostimulation device for treating chronic
pain that was launched in Q2 2015. DPNCheck is a point-of-care
diagnostic device that provides accurate and cost-effective screening,
diagnosis and monitoring of peripheral neuropathies including diabetic
peripheral neuropathy (DPN).
Recent Highlights:
-
Quell shipments totaled 12,086 devices and 14,391 electrode reorder
packages with a total invoiced value of $2.90 million in Q3 2016. This
was an increase from 11,201 devices and 10,237 electrode reorder
packages with a total invoiced value of $2.53 million in Q2 2016.
-
The Company announced that a clinical study by Brigham and Women's
Hospital in Boston will assess the utility of Quell technology in
patients with chronic low back pain.
-
DPNCheck shipments in Q3 2016 reached a 4 year high of 57,400
biosensors, up 45% from 39,500 biosensors in Q3 2015.
-
Final DPNCheck regulatory approval was obtained from the China Food
and Drug Administration.
-
A patent was issued in China for the core DPNCheck technology.
"We are pleased with our progress in the third quarter. Our marketing
focus for Quell continues to be on building widespread brand awareness
through TV and on-line promotion, as well as developing retail channel
experience," said Shai N. Gozani, M.D., Ph.D., President and Chief
Executive Officer of NeuroMetrix. "We are optimistic that the next phase
of retail expansion will occur in the first half of 2017. Our DPNCheck
efforts remain centered on building the Medicare Advantage business
along with international expansion in partnership with local
distributors. We are collaborating with Omron Medical Devices (Beijing)
Co., Ltd. to launch DPNCheck into the large China diabetes market. We
are planning a limited launch this quarter followed by broader market
roll-out starting in the first half of 2017."
Financial Highlights:
The Company reported its financial highlights results for Q3 2016. Total
revenues were $3.39 million versus $2.05 million for Q3 2015, an
increase of 65%. Gross margin was 40.1% of total revenues, reduced from
45.5% in Q3 2015, reflecting a higher weighting of lower margin Quell
devices as the Company builds its installed base. Operating expenses
increased to $5.33 million compared to $4.29 million in Q3 2015,
reflecting Quell marketing and promotion. Loss from operations was $3.97
million in Q3 2016 versus $3.36 million Q3 2015. After interest income
and changes in fair value of warrant liabilities, net loss per common
share was $0.76 in Q3 2016 and $1.06 in Q3 2015. Net cash usage in Q3
2016 was $3.76 million, down from $4.20 million in Q2 2016. The Company
ended Q3 2016 with cash and cash equivalents of $7.57 million.
For the nine months ended September 30, total revenues were $8.31
million in 2016 compared to $4.56 million in 2015. Loss from operations
was $12.34 million for the nine months ended September 30, 2016 versus
$9.96 million for the nine months ended September 30, 2015. After
interest income, changes in fair value of warrant liabilities and deemed
dividend earnings per share charges related to equity offerings, net
loss per common share was $7.01 in the nine months ended September 30,
2016 and $4.06 in the nine months ended September 30 2015.
Company to Host Live Conference Call and Webcast
NeuroMetrix management will host a conference call today, October 20,
2016 at 8:00 a.m., Eastern Time. To access the call in the United
States, dial (844) 787-0799 and use the confirmation code 89762513.
Internationally, the conference call may be accessed by dialing (661)
378-9630 and using the same confirmation code. The call will also be
webcast and will be accessible from the Company's website at http://www.NeuroMetrix.com
under the "Investor Relations" tab. A replay of the conference call will
be available starting two hours after the call by dialing 855-859-2056,
domestically and 404-537-3406, internationally. The confirmation code to
access the replay is 89762513. The replay will be available for one week
after the conference call.
About NeuroMetrix
NeuroMetrix is a commercial stage, innovation driven healthcare company
combining bioelectrical and digital medicine to address chronic health
conditions including chronic pain, sleep disorders, and diabetes. The
company's lead product is Quell, an over-the-counter wearable
therapeutic device for chronic pain. Quell is integrated into a digital
health platform that helps patients optimize their therapy and decrease
the impact of chronic pain on their quality of life. The company also
markets DPNCheck®, a rapid point-of-care test for diabetic
neuropathy, which is the most common long-term complication of Type 2
diabetes. The company maintains an active research effort and has
several pipeline programs, including a therapeutic device for restless
leg syndrome. The company is located in Waltham, Massachusetts and was
founded as a spinoff from the Harvard-MIT (News - Alert) Division of Health Sciences
and Technology in 1996. For more information, please visit www.NeuroMetrix.com.
Safe Harbor Statement
The statements contained in this press release include forward-looking
statements within the meaning of Section 27A of the Securities Act of
1933, as amended, and Section 21E of the Securities Exchange Act of
1934, as amended, including, without limitation, statements regarding
the company's or management's expectations regarding the business, as
well as events that could have a meaningful impact on the company's
revenues. While the company believes the forward-looking statements
contained in this press release are accurate, there are a number of
factors that could cause actual events or results to differ materially
from those indicated by such forward-looking statements, including,
without limitation, estimates of future performance, and the ability to
successfully develop, receive regulatory clearance, commercialize and
achieve market acceptance for any products. There can be no assurance
that future developments will be those that the company has anticipated.
Such forward-looking statements involve known and unknown risks,
uncertainties and other factors including those risks, uncertainties and
factors referred to in the company's most recent Annual Report on Form
10-K, Quarterly Reports on Form 10-Q, as well as other documents that
may be filed from time to time with the Securities and Exchange
Commission or otherwise made public. The company is providing the
information in this press release only as of the date hereof, and
expressly disclaims any intent or obligation to update the information
included in this press release or revise any forward-looking statements.
|
|
|
|
|
|
|
|
|
|
NeuroMetrix, Inc.
|
Condensed Statements of Operations
|
(Unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Quarters Ended September 30,
|
|
|
|
Nine months Ended September 30,
|
|
|
|
|
|
2016
|
|
|
|
2015
|
|
|
|
2016
|
|
|
|
2015
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenues
|
|
|
|
$
|
3,389,427
|
|
|
|
$
|
2,054,432
|
|
|
|
$
|
8,312,096
|
|
|
|
$
|
4,562,379
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of revenues
|
|
|
|
|
2,031,823
|
|
|
|
|
1,119,186
|
|
|
|
|
5,086,706
|
|
|
|
|
2,351,479
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross profit
|
|
|
|
|
1,357,604
|
|
|
|
|
935,246
|
|
|
|
|
3,225,390
|
|
|
|
|
2,210,900
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and development
|
|
|
|
|
1,202,651
|
|
|
|
|
940,794
|
|
|
|
|
3,487,291
|
|
|
|
|
2,825,589
|
|
Sales and marketing
|
|
|
|
|
2,959,311
|
|
|
|
|
1,965,627
|
|
|
|
|
8,199,469
|
|
|
|
|
5,183,595
|
|
General and administrative
|
|
|
|
|
1,165,815
|
|
|
|
|
1,386,170
|
|
|
|
|
3,882,461
|
|
|
|
|
4,157,082
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total operating expenses
|
|
|
|
|
5,327,777
|
|
|
|
|
4,292,591
|
|
|
|
|
15,569,221
|
|
|
|
|
12,166,266
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss from operations
|
|
|
|
|
(3,970,173
|
)
|
|
|
|
(3,357,345
|
)
|
|
|
|
(12,343,831
|
)
|
|
|
|
(9,955,366
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest income
|
|
|
|
|
5,772
|
|
|
|
|
1,761
|
|
|
|
|
17,030
|
|
|
|
|
3,350
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Change in fair value of warrant liability
|
|
|
|
|
56,248
|
|
|
|
|
151,806
|
|
|
|
|
227,873
|
|
|
|
|
3,473,804
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss
|
|
|
|
$
|
(3,908,153
|
)
|
|
|
$
|
(3,203,778
|
)
|
|
|
$
|
(12,098,928
|
)
|
|
|
$
|
(6,478,212
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss per common share applicable to common stockholders, basic
and diluted
|
|
|
|
$
|
(0.76
|
)
|
|
|
$
|
(1.06
|
)
|
|
|
$
|
(7.01
|
)
|
|
|
$
|
(4.06
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
NeuroMetrix, Inc.
|
Condensed Balance Sheets
|
(Unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
September 30, 2016
|
|
|
|
December 31, 2015
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents
|
|
|
|
$
|
7,568,186
|
|
|
|
$
|
12,462,872
|
Other current assets
|
|
|
|
|
3,024,234
|
|
|
|
|
2,749,509
|
Noncurrent assets
|
|
|
|
|
756,312
|
|
|
|
|
887,220
|
Total assets
|
|
|
|
$
|
11,348,732
|
|
|
|
$
|
16,099,601
|
|
|
|
|
|
|
|
|
|
|
|
Current liabilities
|
|
|
|
$
|
3,586,761
|
|
|
|
$
|
3,256,590
|
Common stock warrants
|
|
|
|
|
52,430
|
|
|
|
|
280,303
|
Stockholders' equity
|
|
|
|
|
7,709,541
|
|
|
|
|
12,562,708
|
Total liabilities and stockholders' equity
|
|
|
|
$
|
11,348,732
|
|
|
|
$
|
16,099,601
|
|
|
|
|
|
|
|
|
|
|
|
View source version on businesswire.com: http://www.businesswire.com/news/home/20161020005142/en/
[ Back To Homepage ]
|